OncoMatch/Clinical Trials/NCT06210815
A Study of HLX42 in Advanced/Metastatic Solid Tumors
Is NCT06210815 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies HLX42 for solid tumor and nsclc.
Treatment: HLX42 — This study is an open-label first-in-human phase I clinical study to evaluate the safety and tolerability of HLX42.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Tumor Agnostic
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Lab requirements
Blood counts
adequate organ functions as confirmed by laboratory tests within 7 days prior to the first administration
Kidney function
adequate organ functions as confirmed by laboratory tests within 7 days prior to the first administration
Liver function
adequate organ functions as confirmed by laboratory tests within 7 days prior to the first administration; for patients with hepatocellular carcinoma, Child-Pugh score must be A
Adequate organ functions as confirmed by laboratory tests within 7 days prior to the first administration of the investigational product; For patients with hepatocellular carcinoma, Child-Pugh score must be A
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06210815 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages